A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma (study 205715)
Active, not recruitingNL-OMON45467
GlaxoSmithKlineasthma
Start: 2016-11-14Target: 40Updated: 2024-02-28